Browse more cannabis research, findings, methods, and limitations.
Field sobriety tests alone misidentified 49% of sober people as cannabis-impaired, but adding a 2 ng/mL oral fluid THC cutoff eliminated all false positives.
CBD combined with blood pressure drug losartan synergistically reduced brain cell inflammation by 80%, far exceeding either drug alone (22-26%).
Tamoxifen disrupted the natural cycling of endocannabinoid levels across the estrous cycle in rat brains, reducing AEA levels and altering enzyme expression patterns.
Pregnant cannabis users perceived it as safer than medications, wanted honest conversations with obstetricians, and valued having their motivations for use acknowledged.
A scoping review of 39 studies found cannabis is not recommended for ADHD: the only RCT showed no significant effect, and most studies indicated worsening or no improvement.
Prenatal THC exposure created psychosis vulnerability in male but not female offspring, triggered by later stress or THC. The neurosteroid pregnenolone reversed these effects.
A review of cyclic vomiting syndrome highlights that cannabis is commonly used for symptom relief, but cannabinoid hyperemesis syndrome may be a subset where cannabis causes the problem.
VA patients with opioid addiction and co-occurring cannabis or alcohol disorders were 20-22% less likely to start opioid treatment medications and 5-6% less likely to continue them.
New psychoactive substances including synthetic cannabinoids may accumulate in breast milk, posing underrecognized risks to nursing infants that healthcare providers often miss.
Cannabinoid synthesis genes are active in cannabis seeds before germination, with CBCA appearing as the first cannabinoid shortly after emergence across multiple chemotypes.
Legal Canadian cannabis had 6% pesticide positivity with trace levels, while illicit cannabis had 92% positivity with 23 pesticides at up to 1,000x higher concentrations.
An incarcerated man developed air leaks in multiple body cavities after synthetic cannabinoid use, highlighting severe toxicity risks and healthcare access concerns in prison settings.
Cannabis used for severe morning sickness may actually be causing the vomiting via cannabinoid hyperemesis syndrome, creating a dangerous diagnostic trap in pregnancy.
A new CB2-selective compound (7b5) killed aggressive breast cancer cells and reduced inflammation without activating the CB1 receptor responsible for cannabis's high.
A controlled trial found the lowest CBD:THC ratio (1:1) best reduced THC-induced psychotic symptoms, with higher CBD providing no additional protection.
A bibliometric analysis of PTSD phytochemical research shows a paradigm shift from cannabis abuse concerns toward psychedelic medicine since 2015.
Mice lacking CB2 cannabinoid receptors were protected from food addiction, while those overexpressing CB2 became vulnerable, identifying a new therapeutic target for compulsive eating.
A Brazilian school prevention program reduced teen alcohol use by changing beliefs about alcohol, but had no effect on marijuana, tobacco, or inhalant use.
CBD dose-dependently reversed anxiety, withdrawal symptoms, and brain gene expression changes during acute alcohol withdrawal in mice, specifically in the nucleus accumbens.
A review maps expanding CB2 receptor drug development from pain/inflammation into CNS disorders, bone disease, and cancer, aided by the recently solved receptor structure.
Daily stress equally escalated cocaine use in male and female rats, with the CB1 receptor antagonist rimonabant reducing intake through sex-specific mechanisms.
Minor cannabinoids CBD, CBG, CBN, and CBC all killed A375 melanoma cells, while CBN uniquely inhibited tyrosinase — the key enzyme in skin pigmentation.
Converting CBD to delta-8 THC produces numerous untested chemical byproducts sold to consumers without quality control, with EVALI cases and ~2% fatality rates reported.
A clinical guide details the rising cannabis toxicity presentations in children (accidental edibles) and adolescents (chronic use/hyperemesis), with practical evaluation and management advice.
In real-world practice, 75% of refractory epilepsy patients stayed on Epidiolex long-term, with fewer GI and liver side effects than clinical trials and 53% reducing other medications.
For teen cannabinoid hyperemesis syndrome, benzodiazepines and haloperidol worked better than standard anti-nausea drugs, with minimal side effects in either group.
Of 969 chronic pain patients, 46% currently used cannabinoids with large reported benefits, while 32% never tried them due to clinician hesitancy, illegality, or lack of FDA approval.
Among 434 Canadian endometriosis patients using an average of 7 alternative therapies, cannabis and heat were rated most effective — but 62% still felt pain was inadequately managed.
Cannabis users with heart disease had much higher rates of ventricular tachycardia (48%) than healthy cannabis users (6%), though overall arrhythmia burden was similar to non-using heart patients.
A spectroscopic method classified cannabis chemotypes with 100% accuracy and quantified THC/CBD with HPLC-equivalent precision in under 45 seconds per sample.
The largest published collection of synthetic cannabinoid drugs was pharmacologically profiled, revealing structure-activity patterns and confirming significant neurotoxicity.
Of 2,133 crash-involved THC-positive drivers in Norway, 84% also tested positive for sedatives, stimulants, or alcohol, complicating cannabis-specific impairment attribution.
A systematic review of patient experiences found medical cannabis users face stigma, administrative hurdles, adverse effects, and dependence fears that shape their treatment experience.
Near-infrared spectroscopy accurately predicted 10 of 12 cannabinoid levels in cannabis flower using a diverse global panel, offering rapid and economical testing.
Prenatal alcohol and marijuana exposure predicted distinct patterns of cannabis use transitions from ages 16 to 22, independent of peer and environmental factors.
CBD showed strong synergistic anti-seizure effects when combined with ganaxolone or midazolam in an adult mouse model of refractory focal epilepsy.
Meta-analysis of 14 studies confirms the Marijuana Purchase Task validly measures cannabis reinforcement, with intensity and elasticity as the strongest indicators.
Cannabis legalization did not broadly change childhood asthma rates, but recreational legalization states showed increased asthma among teens and minority youth.
THC-positive psychosis patients in the ER required more restraints and emergency medications but were not more likely to be hospitalized or return within 90 days.
Review covers how cannabis plants produce cannabinoids, their structural classifications, and their therapeutic potential across diseases and antimicrobial applications.
A cross-sectional analysis of US poison center data found that suspected suicidal cannabis exposures increased during the COVID-19 pandemic, reflecting broader trends in both mental health crises and cannabis availability.
Genetic analysis identifies PDE4B and hyaluronidase as drug repurposing targets for cannabis use disorder, with links to immune and inflammatory pathways.
Survey of 236 IBD patients using medical cannabis found fewer ER visits, reduced symptom impact, and mostly mild side effects like euphoria.
In a national sample of 1,126 Gulf War veterans, cannabis use was independently associated with suicidal ideation and elevated suicide risk.
Large survey of nearly 5,000 kratom users finds those with psychiatric conditions report improved mood, often using kratom alongside cannabis and benzodiazepines.
Conditional knockout study proves CB2 receptors on peripheral sensory neurons, not immune cells, mediate the anti-pain effects of CB2 agonist LY2828360.
Post-legalization survey of 1,496 Canadian students finds rural youth use more cannabis, but driving-after-use patterns vary by province and setting.
Review finds 23% ADHD prevalence in substance use disorder populations, with cannabis as the most common illicit drug used and weak evidence for medical cannabis as treatment.
Mouse study finds combined prenatal immune activation and adolescent THC produce subtle brain changes and anxiety behaviors, with sex differences in brain-behavior patterns.
Double-blind crossover study shows single-dose CBD reduces insula activity during salience processing in early psychosis patients.